Research Article
Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia
Table 4
Factors associated with the utilization of ACEIs (n=308).
| | Variables | ACEIs use | COR (95% CI) | p-value | AOR (95%CI) | p-value | | No, n (%) | Yes, n (%) |
| | Age category | | | | | | |
| | <65 | 62 (79.5) | 165 (71.7) | 1 | 1 | 1 | 1 |
| | >=65 | 16 (20.5) | 65 (28.3) | 1.53 (0.82-2.84) | 0.181 | 1.02 (0.47-2.19) | 0.964 |
| | Hospitalization in the last one year | | | | | | |
| | No | 39 (50.0) | 93 (40.4) | 1 | 1 | 1 | 1 |
| | Yes | 39 (50.0) | 137 (59.6) | 1.47 (0.88-2.47) | 0.141 | 1.33 (0.69-2.55) | 0.394 |
| | Number of comorbidities | | | | | | |
| | <2 | 36 (46.2) | 79 (34.3) | 1 | 1 | 1 | 1 |
| | >=2 | 42 (53.8) | 151 (65.7) | 1.64 (0.97-2.76) | 0.064 | 1.02 (0.51-2.01) | 0.964 |
| | NYHA class | | | | | . | |
| | I | 3 (3.75) | 19 (8.3) | 1 | 1 | 1 | 1 |
| | II | 12 (15) | 125 (54.8) | 0.47 (0.10-2.15) | 0.331 | 1.11 (0.13-9.55) | 0.925 |
| | III | 65 (81.3) | 84 (36.8) | 0.19 (0.04-0.83) | 0.027 | 0.12 (0.02-0.98) | 0.047 |
| | Ischemic heart disease | | | | | | |
| | No | 48 (61.5) | 121 (52.6) | 1 | 1 | 1 | 1 |
| | Yes | 30 (38.5) | 109 (47.4) | 1.44 (0.85-2.44) | 0.172 | 1.23 (0.60-2.51) | 0.579 |
| | Hypertension | | | | | | |
| | No | 72 (92.3) | 153 (66.5) | | | | |
| | Yes | 6 (7.7) | 77 (33.5) | 6.04 (2.51-14.51) | P<0.001 | 5.82 (2.16-15.71 | 0.001 |
| | Valvular heart disease | | | | | | |
| | No | 42 (53.8) | 199 (86.5) | 1 | 1 | 1 | 1 |
| | Yes | 36 (46.2) | 31 (13.5) | 0.18 (.10-0.32) | P<0.001 | 0.27 (0.13-0.56) | 0.001 |
| | Diabetes mellitus | | | | | | |
| | No | 75 (96.2) | 181 (78.7) | 1 | 1 | 1 | 1 |
| | Yes | 3 (3.8) | 49 (21.3) | 5.91 (1.78-19.63) | 0.004 | 3.84 (1.07-13.86) | 0.040 |
|
|
NYHA, New York Heart Association, ACEIs, angiotensin converting enzyme inhibitors, COR, crude odds ratio, AOR, adjusted odds ratio, and CI, confidence interval.
|
